EUÀÇ COVID-19 ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå ÀλçÀÌÆ®, µ¿Çâ, ¼ºÀå ±âȸ
EU COVID-19 Vaccine and Therapeutics Insights, Trends, and Growth Opportunities
»óǰÄÚµå : 1043345
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2021³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 55 Pages
US $ 2,450 £Ü 3,129,000
Web Access (Regional License) help
¸®¼­Ä¡»çÀÇ À¥»çÀÌÆ®¿¡ ·Î±×ÀÎÇÒ ¼ö ÀÖ´Â ÆÐ½º¿öµå°¡ ¹ß±ÞµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµË´Ï´Ù. µ¿ÀÏ ±¹°¡ ³»¿¡ ÀÖ´Â »ç¾÷ÀåÀÇ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, ÀÌ¿ë Àοø¼ö Á¦ÇÑÀº ¾ø½À´Ï´Ù. ÅØ½ºÆ® µîÀÇ PDF ³»¿ë ÆíÁýÀº ºÒ°¡´ÉÇÕ´Ï´Ù. ÀμâȽ¼ö¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

EUÀÇ µðÁöÅÐ ¹é½Å Á¢Á¾ ¿©±ÇÀ̳ª ¿µ±¹ÀÇ NHS COVID Pass ¾Û µîÀº À¯·´ÀÇ ¾ÈÀüÇÑ Àç°³¿Í COVID-19ÀÇ ¿ì·ÁµÇ´Â º¯ÀÌü ±Øº¹¿¡ ÀÏÁ¤ÇÑ È¿°ú°¡ ÀÖÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹é½Å Á¢Á¾Àº ºü¸¥ ¼Óµµ·Î ÁøÇàµÇ°í ÀÖÁö¸¸, Ä·ÆäÀÎÀÇ ÇâÈÄ µ¿ÇâÀ» Á¿ìÇÏ´Â ¿äÀÎÀ¸·Î¼­´Â Á¤Ä¡Àû/Á¾±³Àû »óȲ, ¹é½ÅÀÇ °¡¿ë¼º°ú ¾×¼¼½º, ƯÈ÷ ÀþÀºÃþÀÇ ¹é½Å Á¢Á¾ ÁÖÀú µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ºÒ°¡¸®¾Æ, ·ç¸¶´Ï¾Æ, ¶óÆ®ºñ¾Æ¿¡¼­´Â ÁßÀ¯·´/µ¿À¯·´(CEE)ÀÇ ³·Àº ¹é½Å Á¢Á¾·üÀÌ COVID-19 ±ÞÁõ(ƯÈ÷ µ¨Å¸ÁÖ)¿¡ ¹ÚÂ÷¸¦ °¡Çϸç ÀÇ·á À§±â¸¦ ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

EUÀÇ COVID-19 ¹é½Å ¹× Ä¡·áÁ¦(COVID-19 Vaccine and Therapeutics) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, Àü·«Àû Çʼö ¿ä°Ç, ¼ºÀå ±âȸ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Àü·«Àû Çʼö ¿ä°Ç

¹é½Å ¹× Ä¡·áÁ¦ ÇÏÀ̶óÀÌÆ®

¼ºÀå ±âȸ ºÐ¼®

¼¼°èÀÇ COVID-19 ¹é½Å ¿¬±¸°³¹ß »óȲ

¼¼°èÀÇ COVID-19 Ä¡·áÁ¦ ¿¬±¸°³¹ß »óȲ

¼¼°è ³×Æ®¿öÅ©¸¦ È®´ëÇϱâ À§ÇÑ ¹é½Å Á¦Á¶¾÷üÀÇ Àü·«

EUÀÇ COVID-19 ¹é½Å Á¢Á¾ Àü°³

COVID-19¿ÍÀÇ ½Î¿ò¿¡¼­ µðÁöÅÐ ±â¼úÀÇ ¿ªÇÒ

¼ºÀå ±âȸ ¿µ¿ª

LSH 22.01.10
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Future Growth Potential Driven by Capabilities and Expertise in Vaccine Manufacturing

With this research service, Frost & Sullivan's Healthcare and Life Sciences team provides critical insights into the European Union and UK COVID-19 vaccine and therapeutics market. The report analyzes COVID-19 vaccines and therapeutics in development and delves into supply chain considerations and requirements to manage distribution. Importantly, the study identifies actionable growth opportunities for industry participants. Like the United States, the European Union received criticism for vaccine nationalism, but it is taking steps to encourage global vaccine access. It has launched the Team Europe initiative for improving manufacturing and access to vaccines, medicines, and health technologies in Africa.

Initiatives such as the EU Digital Vaccination Passport and UK NHS COVID Pass app will help Europe in safe reopening and overcoming COVID-19 variants of concern to a certain extent. Although vaccinations are progressing at a fast pace, factors that will determine campaigns' future course include political and religious situations, vaccine availability and access, and vaccine hesitancy specifically in younger population groups. The low vaccination rate in Central and Eastern Europe (CEE) is fueling another COVID-19 surge (especially because of the Delta variant) and causing a healthcare crisis in Bulgaria, Romania and Latvia.

Topics covered include:

Table of Contents

Strategic Imperatives

Vaccine and Therapeutics Highlights

Growth Opportunity Analysis

Global COVID-19 Vaccine R&D Landscape

Global COVID-19 Therapeutic R&D Landscape

Vaccine Manufacturer Strategies to Scale Up Their Global Network

EU COVID-19 Vaccination Rollout

Role of Digital Technology in the COVID-19 Fight

Growth Opportunity Universe

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â